Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 with DAC Dosage Guide, Benefits & Side Effects

CJC-1295 with DAC Dosage Guide, Benefits & Side Effects CJC-1295 with DAC extends GH and IGF-1 elevation for up to a week per dose, supporting lean mass, recovery, and sleep. Explore the research. Chemical Makeup 29 Amino Acids CJC-1295 with DAC Tyr Position 1

By Recovery & Performance Peptides Editorial Team

CJC-1295 with DAC Dosage Guide, Benefits & Side Effects

CJC-1295 with DAC extends GH and IGF-1 elevation for up to a week per dose, supporting lean mass, recovery, and sleep. Explore the research.

Chemical Makeup

29

Amino Acids

CJC-1295 with DAC

Tyr

Position 1

Ala

Position 2

Asp

Position 3

Position 4

Ile

Position 5

Phe

Position 6

Thr

Position 7

Gln

Position 8

Ser

Position 9

Position 10

Arg

Position 11

Lys

Position 12

Val

Position 13

Leu

Position 14

Position 15

Position 16

Position 17

Position 18

Position 19

Position 20

Position 21

Position 22

Position 23

Position 24

Position 25

Position 26

Position 27

Position 28

Position 29

As seen on

CJC-1295 with DAC Dosage Guide for Fat Loss / MuscleCJC-1295 with DAC Dosage Calculator

CJC-1295 with DAC is a long-acting peptide that keeps growth hormone levels steadily elevated over time.

Vial size

2 mg

Bacteriostatic water

2 mL

Dosing

1–2 mg

Frequency

Weekly

Cycle

8–12 weeks

Benefit

Fat Loss / Muscle

What is CJC-1295 with DAC?

CJC-1295 with DAC is a longer-acting version of CJC-1295 that sticks to a protein in your blood, which lets it stay active in the body for about a week instead of just hours. This means it keeps growth hormone levels elevated with far fewer injections, often just once or twice a week. It's used in research and some clinical settings for growth hormone support, body composition, and anti-aging goals.

Weight

Research targets include appetite regulation, fat metabolism, and body composition.

Growth

Research targets include growth hormone signaling, IGF-1 pathways, and tissue development.

cjc1

Is CJC-1295 with DAC FDA approved?

CJC-1295 with DAC is not an FDA-approved drug. It is intended for research purposes only and is not approved for human consumption, diagnostic, or therapeutic use.

Research Use Only

CJC-1295 with DAC has not been evaluated by the FDA for safety or efficacy in humans.

No Clinical Oversight

Not manufactured under FDA-regulated quality or clinical standards.

Unregulated Sourcing

Purity, dosing, and sourcing are not verified through FDA testing or oversight.

Our top-rated vendor

View all vendors

Our rankings are based solely on third-party lab testing rigor, COA transparency, and pricing — no paid placements, no affiliate influence. We update this list as new data comes in.

Based on current scores, this vendor ranks highest across those criteria.

Protide Health

#1 Rated Research Peptide Supplier

How Does CJC-1295 with DAC Work?

It binds the same pituitary receptor as the natural hormone GHRH, prompting the gland to release growth hormone. A special chemical tag lets it grab onto a protein that's always floating in the blood, turning it into a slow-release depot that can keep growth hormone elevated for over a week per dose.

Binds the GHRH receptor

Prompts the pituitary gland to release growth hormone.

Locks onto a blood protein

A chemical tag lets it attach to albumin, always present in the blood.

Slow-release depot

Keeps growth hormone elevated for over a week per dose.

CJC-1295 with DAC Targeted areas

How to reconstitute CJC-1295 with DAC

The materials you'll need and step-by-step instructions for safely mixing CJC-1295 with DAC with bacteriostatic water.

Materials needed

Your CJC-1295 with DAC vial (lyophilized)

Alcohol swabs

Bacteriostatic sterile water

3 mL syringes (Luer Lock tip)

25G or 27G needles (Luer Lock). Other gauges may also be acceptable.

Sharps container (optional)

Remove the caps

Sanitize the rubber stoppers

Attach the needle

Draw the bac water

Pull back on the plunger to draw your desired volume of bacteriostatic water. If you overfill, just push the excess back in until you reach the right marker on the syringe.

Insert the needle into the CJC-1295 with DAC vial

With the bac water in your syringe, insert the needle into the CJC-1295 with DAC vial at a slight angle to avoid pressure buildup.

Release the water gently

Let the water run gently down the side of the vial. Don't inject it forcefully.

Swirl to dissolve

Avoid shaking. Gently swirl, flip, and roll the vial to dissolve the powder.

Check for full dissolution

Cap, dispose, and store

How to Store CJC-1295 with DAC

Freeze the dry powder for up to two years. Once mixed with liquid, refrigerate and use within about a month; don't freeze it again once mixed.

Lyophilized Storage

-20°C, stable up to 24 months.

Reconstituted Storage

2–8°C, use within 28 days.

Handling Notes

Do not freeze after reconstitution.

What Are the Benefits of CJC-1295 with DAC?

What research says it may help with, and how it works in the body.

growth hormone

Provides a steady release of growth hormone that lasts six to eight days from a single injection.

Raises levels of the hormone IGF-1 substantially, and keeps them elevated for an extended period.

Only needs to be taken about once a week, making it simple to use.

body composition

Keeping growth hormone levels raised continuously helps the body break down and use stored fat for energy.

Creates ongoing conditions in the body that favor building muscle, supporting the process of making new muscle protein.

antiaging

Speeds up healing and recovery after exercise or injury.

What Are the Side Effects of CJC-1295 with DAC?

Who should avoid it, warning signs to watch for, and what to know before combining it with other compounds.

Who Should Avoid It

Diabetes history

Cancer history

Predisposed sleep apnea

Stop Right Away If You Notice

Severe joint pain or carpal tunnel syndrome

Excessive water retention affecting daily life

Numbness or tingling in extremities

Significant blood glucose dysregulation

Signs of acromegaly (jaw growth, hand/feet enlargement)

Persistent lethargy indicating adrenal effects

Milder Signs to Watch For

How Long Should a CJC-1295 with DAC Cycle Last?

This breaks down how long a typical CJC-1295 with DAC cycle runs and what research suggests happens at each stage. Research shows that staying on a peptide continuously, without a break, may make it less effective over time.

That's why most research protocols build in a break between cycles, often called a washout period, to let the body reset before starting again.

Related peptides

Metabolic

5am

Longevity

5-Amino-1MQ

Preclinical

aod

AOD-9604

Experimental

adi

Adipotide

Phase 1

bam

BAM-15

Cheat Sheets Featuring CJC-1295 with DAC

See how CJC-1295 with DAC fits into a broader research stack with these free downloadable cheat sheets. Each one includes reference dose ranges, dosing frequency, and half-life for every peptide it covers. For research purposes only.

13 peptides

78 peptides

19 peptides

CJC-1295 with DAC Research References

It is a phase 2 compound

CJC-1295 with DAC is a phase 2 compound

12 subjects; sustained GH and IGF-1 elevation for 6-10 days post-injection with peak 2-4x baseline.

2006

Frequently Asked Questions About CJC-1295 with DAC

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

What is CJC-1295 with DAC and how does it work?

CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC), a molecular tag that binds covalently to albumin in the blood. This albumin binding protects the peptide from rapid enzymatic breakdown, allowing it to keep stimulating the pituitary gland to release growth hormone (and, downstream, IGF-1) over an extended period rather than in a single short pulse. It is sold and studied strictly as a research chemical.

What is the difference between CJC-1295 with DAC and CJC-1295 without DAC (Mod GRF 1-29)?

The core peptide sequence is essentially the same GHRH analog, but the DAC-modified version has a half-life of roughly 5-8 days because it binds albumin, versus about 30 minutes for the non-DAC version (also called Mod GRF 1-29). Because of this, CJC-1295 with DAC is typically dosed once or twice per week to produce a sustained elevation in GH/IGF-1, while the no-DAC version is dosed daily or multiple times a day to produce shorter GH pulses that more closely mimic the body's natural release pattern.

What dosing protocols are commonly discussed for CJC-1295 with DAC?

In research and community protocols, doses in the range of roughly 1-2 mg (1,000-2,000 mcg) once or twice weekly are commonly cited, with some sources suggesting a more conservative starting point around 0.5 mg (500 mcg) weekly. These figures come from vendor and community protocol pages rather than approved clinical dosing guidance, and actual protocols used in published research vary.

Is CJC-1295 with DAC commonly stacked with other peptides?

Yes, it is frequently discussed alongside a growth hormone secretagogue such as Ipamorelin or Ipamorelin/GHRP combinations, on the reasoning that combining a GHRH analog with a ghrelin-receptor agonist may produce a more pronounced GH release than either compound alone. This combination is widely referenced in vendor and enthusiast literature but is not a clinically validated, standardized protocol.

What side effects are reported with CJC-1295 with DAC?

Commonly reported effects include injection-site redness or irritation, flushing, headache, water retention, and joint or muscle stiffness associated with elevated GH/IGF-1. Because it raises GH and IGF-1 for extended periods, sources also note potential effects on blood glucose/insulin sensitivity and, with prolonged continuous use, concern about pituitary desensitization or reduced sensitivity to repeated GHRH stimulation. These reports come from research literature and user/vendor sources rather than controlled long-term safety trials.

Do people cycle CJC-1295 with DAC or take breaks?

Community and vendor protocols often recommend periodic breaks, sometimes cited as every 12-16 weeks, based on the idea that continuous sustained GHRH stimulation could lead to reduced pituitary responsiveness over time. Some who prioritize a shorter, more pulsatile GH release for extended-duration use opt for the non-DAC version instead. There is no standardized, clinically established cycling protocol.

How should CJC-1295 with DAC be stored and reconstituted?

As commonly described for lyophilized (freeze-dried) peptides, the unreconstituted vial is generally stored frozen or refrigerated, protected from light and moisture. Bacteriostatic water is typically used to reconstitute it, added slowly down the side of the vial and mixed by gentle swirling (not shaking) to avoid degrading the peptide. Once reconstituted, it is generally recommended to store the solution refrigerated (roughly 2-8°C) and use it within about 2-4 weeks, without freezing the reconstituted solution.

Is CJC-1295 with DAC legal and approved for human use?

CJC-1295 with DAC is not approved by the FDA or comparable regulators for human use and is sold by suppliers labeled 'for research/laboratory use only, not for human consumption.' Its legal status for personal use varies by country and jurisdiction, and information about dosing, effects, and safety is drawn from preclinical/clinical research literature and community reporting rather than approved medical guidance.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosages

Dosages in research are individualized and typically administered via subcutaneous injection. Common protocols include: 100 mcg per injection, 2 times per week. Cycling regimens (e.g., 8-12 weeks on, 4 weeks off) to prevent desensitization. Often dosed at bedtime to align with natural GH pulses. Dosing should be tailored to research goals and subject response, with careful monitoring.
STORAGE

Reconstitution and Storage: The Step Most Protocols Get Wrong

CJC-1295 is supplied as a lyophilised (freeze-dried) powder that must be reconstituted with bacteriostatic water before injection. The reconstitution process is where most peptide protocols fail. Not from contamination, but from introducing air bubbles that denature the peptide during subsequent draws. When you inject air into the vial to equalise pressure (a common technique), you create turbulence that causes peptide molecules to aggregate at the air-water interface. Over multiple draws, this aggregation compounds, reducing bioactivity by 15–30% even when the solution is stored correctly. Correct reconstitution: inject bacteriostatic water slowly down the side of the vial (not directly onto the lyophilised cake), allow it to dissolve passively without shaking, and draw each dose by inserting the needle and pulling back the plunger without injecting air first. Store the reconstituted vial upright in the refrigerator at 2–8°C, and use a fresh alcohol swab on the rubber stopper before every draw to prevent bacterial contamination. Once reconstituted, CJC-1295 remains stable for 28 days when refrigerated. Any temperature excursion above 8°C (such as leaving it on the counter for 2+ hours) causes irreversible aggregation that neither appearance nor potency testing at home can detect. Unreconstituted lyophilised powder is stable for 24+ months when stored at −20°C. Our lyophilised peptides at Real Peptides are synthesised in small batches with exact amino-acid sequencing, third-…
02

Question drills

Open a question for its connected answer.

01What If I'm Already Taking Other Peptides Like BPC-157 or TB-500?+

Stacking peptides is common in research contexts, though direct interaction studies don't exist. BPC-157 and TB-500 act through different pathways (angiogenesis, actin regulation, inflammatory modulation) than CJC-1295's GH-IGF-1 axis. The mechanisms are theoretically complementary rather than redundant. If you're considering multi-peptide protocols, staging them (e.g., BPC-157 during weeks 1–4, CJC-1295 during weeks 3–12) may reduce the number of simultaneous variables and allow clearer assessment of individual contributions.

SOURCE / realpeptides.co ↗
02What If IGF-1 Levels Don't Elevate as Expected After CJC-1295 Administration?+

Measure baseline IGF-1 before dosing and retest at 96 hours. Not 24 or 48 hours. If IGF-1 remains flat at the 96-hour mark, the issue is likely either receptor saturation from prior GH exposure, hepatic GH receptor downregulation, or peptide degradation due to improper storage. CJC-1295 with DAC must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, it remains stable at 2–8°C for 28 days but degrades rapidly above 8°C. A single temperature excursion can denature the peptide structure entirely.

SOURCE / realpeptides.co ↗
03What If Long-Term Safety Data Beyond 12 Weeks Doesn't Exist in Animal Models?+

It largely doesn't—most cjc-1295 animal research spans 8–12 weeks, occasionally extending to 16 weeks in primate models. Chronic effects (pituitary adenoma risk, joint degeneration, insulin resistance progression) require 6–12 month timelines to manifest, and no published study has run that duration in a controlled animal cohort. The implication: human use extending beyond 3–4 months operates outside the evidence base established by animal research. That doesn't mean it's unsafe—it means the long-term risk profile is inferred from exogenous GH studies, not directly tested with CJC-1295.

SOURCE / realpeptides.co ↗
04What If GHRH Receptors Downregulate During Extended Use?+

Receptor density remains stable at therapeutic CJC-1295 doses. Downregulation requires continuous maximal stimulation. Something CJC-1295 receptor pharmacology avoids by design. Studies measuring somatotroph GHRH receptor expression after 12 weeks of CJC-1295 administration found no significant reduction in receptor mRNA or surface protein compared to baseline. This is why CJC-1295 maintains efficacy across multi-month protocols without requiring dose escalation. If researchers observe diminishing IGF-1 response over time, the issue is typically at the hepatic level (IGF-1 production) or hypothalamic level (somatostatin tone), not receptor desensitization.

SOURCE / realpeptides.co ↗
05What If the Vial Looks Cloudy After Being Left Out?+

Discard it immediately. Cloudiness indicates either bacterial contamination or peptide aggregation. Both render the solution unusable. Aggregated CJC-1295 cannot be reversed by refrigeration. Contaminated solutions pose sterility risks if used in any research protocol. Cloudiness is a late-stage degradation signal: by the time you see it, the peptide has been compromised for days. Our experience across hundreds of peptide shipments confirms this. Visual changes always lag behind molecular degradation.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

The Future of Research with CJC-1295 GHRH Analog with DAC

As we look ahead in 2026, the potential for the CJC-1295 GHRH analog with DAC in biological research seems boundless. The sustained and physiologically relevant stimulation of GH release it offers makes it an invaluable tool for understanding complex endocrine interactions, metabolic pathways, and regenerative processes. We're seeing more sophisticated experimental designs emerging, leveraging the unique properties of this compound to uncover deeper insights into human physiology and potential therapeutic strategies. Our commitment at Real Peptides is to remain at the forefront of this exciting field, consistently providing the highest quality research materials. We understand that breakthroughs aren't just about discovery; they're also about the unwavering reliability of the tools used to achieve them. We encourage researchers to Explore High-Purity Research Peptides on our site and to connect with our knowledgeable team for any questions regarding the CJC-1295 GHRH analog with DAC or any other compound in our extensive catalog. The journey of discovery is a collective one, and we're proud to be a trusted partner in your vital work.

RESEARCH

GHRH Receptor Signaling: Downstream Research Relevance

When CJC-1295 with DAC (whether bound to albumin or in free form) engages the GHRH receptor (GHRHR) on pituitary somatotroph cells, it initiates the same intracellular signaling cascade as endogenous GHRH. The GHRHR is a G-protein coupled receptor (GPCR) that, upon activation, stimulates adenylyl cyclase through Gs alpha subunit coupling. This raises intracellular cyclic AMP (cAMP), which in turn activates protein kinase A (PKA). PKA phosphorylates downstream targets including transcription factors that drive GH gene expression, and it also modulates calcium channel activity to stimulate GH exocytosis from secretory granules. In research models, sustained GHRHR activation by CJC-1295 with DAC produces amplified GH pulses — the amplitude of individual pulses is increased rather than the baseline (trough) being continuously elevated. This pattern appears to preserve the pulsatile character of GH secretion, which has implications for how researchers interpret the downstream effects on IGF-1 production in the liver and on peripheral tissues.

05

Product & matchup locker

Linked catalog and comparison files.

Continue reading

Related articles

CJC-1295 with DAC - Research Findings

Research Overview: CJC-1295 with DAC Mechanism of action. CJC-1295 with DAC is engineered to bind serum albumin via its Drug Affinity Complex, reducing renal clearance and proteolysis. As a GHRH receptor agonist, it sti…

Read article